Dear DEA-Registered Prescriber:

You are receiving this letter because you recently registered with DEA to prescribe Schedule II or III drugs. The purpose of this letter is to inform you about a Risk Evaluation and Mitigation Strategy (REMS) that has been required by the U.S. Food and Drug Administration (FDA) for all extended-release and long-acting (ER/LA) opioid analgesic drug products.

ER/LA opioid analgesics are used for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Because of the risks of addiction, abuse and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release formulations, reserve ER/LA opioid analgesics for use in patients for whom alternative treatment options (e.g. non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

They can be safe and effective in appropriately selected patients when used as directed. However, opioid analgesics are also associated with serious risks and are at the center of a major public health crisis of increased misuse, abuse, addiction, overdose, and death.

FDA determined that a REMS was necessary to ensure that the benefits of ER/LA opioid analgesics continue to outweigh their risks of adverse outcomes (addiction, unintentional overdose, and death) resulting from inappropriate prescribing, abuse, and misuse. A REMS is a strategy to manage a known or potential serious risk associated with a drug product. In the interest of public health and to minimize the burden on the healthcare delivery system of having multiple unique REMS programs, the pharmaceutical companies subject to this REMS have joined together to implement the REMS for all ER/LA opioid analgesic drug products.

The ER/LA Opioid Analgesic REMS has three principal components:

a) Prescriber training on all ER/LA opioid analgesics,
b) a Patient Counseling Document on Extended-Release/Long-Acting Opioid Analgesics (PCD), and
c) a unique Medication Guide for each ER/LA opioid analgesic drug product.

The branded and generic drug products subject to this REMS include all:

• extended-release, oral-dosage forms containing
  - hydrocodone,
  - hydromorphone,
  - morphine,
  - oxycodone,
  - oxymorphone, or
  - tapentadol;
• fentanyl and buprenorphine-containing transdermal delivery systems; and
• methadone tablets and solutions as well as buprenorphine-containing buccal films that are indicated for use as analgesics.

Prescriber Action

Under the REMS, you are strongly encouraged to do all of the following:

• **Train (Educate Yourself)** - Complete REMS-compliant training on the ER/LA opioid analgesics offered by an accredited provider of continuing education (CE) for your discipline. REMS-compliant training will: (a) be delivered by accredited CE providers; (b) cover all elements of the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics (“FDA Blueprint”); (c) include a knowledge assessment; and (d) be subject to independent audit of content and compliance with applicable accrediting standards.

• **Counsel Your Patients** – Discuss the safe use, serious risks, storage, and disposal of ER/LA opioid analgesics with patients and their caregivers every time you prescribe these medicines. Use the enclosed Patient Counseling Document on Extended-Release/Long-Acting Opioid Analgesics (PCD) to facilitate these discussions.
Prescriber Letter #3

- **Emphasize Patient and Caregiver Understanding of the Medication Guide** - Stress to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an ER/LA opioid analgesic is dispensed to them, as information may have changed.

- **Consider Using Other Tools** - In addition to the PCD, there are other publicly available tools to improve patient, household, and community safety when using ER/LA opioid analgesics, as well as compliance with conditions of treatment, including Patient-Prescriber Agreements (PPAs) and risk assessment instruments.

**REMS-compliant Training Programs**

REMS-compliant training is a critical component of the ER/LA Opioid Analgesics REMS program. REMS-compliant training will focus on the safe prescribing of ER/LA opioid analgesics. The FDA developed core messages to be communicated to prescribers in the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics (“FDA Blueprint”), which is being used by accredited CE providers to develop the REMS-compliant training courses. The Blueprint is available at [http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM515636.pdf](http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM515636.pdf)

REMS-compliant training for prescribers includes both general and product-specific drug information, as well as information on weighing the benefits and risks of opioid therapy, appropriate patient selection, managing and monitoring patients, and counseling patients on the safe use of these drugs. In addition, the education includes information on how to recognize evidence of, and the potential for, opioid misuse, abuse, addiction, and overdose. REMS-compliant training may also be offered by academic institutions or learned societies independent of REMS-related funding. We encourage you to successfully complete REMS-compliant training from an accredited CE provider to improve your ability to prescribe these medications more safely.

For a listing of available REMS-compliant training offered by accredited CE providers under the REMS, visit [www.ER-LA-opioidREMS.com](http://www.ER-LA-opioidREMS.com).

**The Patient Counseling Document on Extended-Release/Long-Acting Opioid Analgesics (PCD)**

Enclosed with this letter is the Patient Counseling Document that was developed under the REMS for ER/LA opioid analgesics and designed to assist you in having important conversations with patients for whom you select an ER/LA opioid analgesic. It contains important safety information common to the drug products subject to this REMS, and includes space for you to write additional information to help your patients use their ER/LA opioid analgesic safely. The PCD should be provided to the patient or their caregiver at the time of prescribing. Patients and their caregivers should be counseled on:

- the importance of taking these medicines exactly as you prescribe them,
- the need to store ER/LA opioid analgesics safely and securely – out of the reach of children, pets, and household members – to avoid risks from unintended exposure,
- the importance of not sharing these medications, even if someone has the same symptoms as the patient, and
- the proper methods of disposal of unneeded ER/LA opioid analgesics.

You can re-order or print additional copies of the PCD from [www.ER-LA-opioidREMS.com](http://www.ER-LA-opioidREMS.com).

**Adverse Event Reporting**

To report all suspected adverse reactions associated with the use of the ER/LA opioid analgesics, contact:

- the pharmaceutical company that markets the specific product, or
- the FDA MedWatch program:
  - by phone at 1-800-FDA-1088 (1-800-332-1088) or
  - online at [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm)

More information about this REMS can be obtained at: [www.ER-LA-opioidREMS.com](http://www.ER-LA-opioidREMS.com) or by calling the ER/LA Opioid Analgesic REMS Call Center at 1-800-503-0784.

Sincerely,

*The ER/LA Opioid Analgesic REMS Companies*